NY-ESO-1抗原肽研究进展

[1] Schultz-Thater E,Noppen C,Gudat F,et al.NY-SEO-1 tumour associated antigen is a cytoplasmic protein detectable by specific monoclonal antibodies in cell lines and clinical specimens. British Journal of Cancer . 2000

[2] Gnjatic S,Atanackovic D,Matsuo M,et al.Cross-presentation of HLA class I epitopes from exogenous NY-ESO-1 polypeptides by nonprofessional APCs. J Immunol . 2003

[3] Romero P,Dutoit V,Rubio-Godoy V,et al.CD8+ T-cell response to NY- ESO- 1: relative antigenicity and in vitro immunogenicity of natural and analogue sequences. Clinical Cancer Research .

[4] Gnjatic S,Nagata Y,Jager E,et al.Strategy for monitoring T cell responses to NY-ESO-1 in patients with any HLA class I allele. Proceedings of the National Academy of Sciences of the United States of America . 2000

[5] Jager E,Nagata Y,Gnjatic S,et al.Monitoring CD8+ T cell responses to NY-ESO-1: correlation of humoral and cellular immune responses. Proceedings of the National Academy of Sciences of the United States of America . 2000

[6] Zarour HM,Maillere B,Brusic V,et al.NY-ESO-1 119-143 is a promiscuous major histocompatibility complex class II T- helper epitope recognized by Th1- and Th2-type tumor-reactive CD4+T cells. Cancer Research . 2002

[7] Jager E,Chen YT,Drijfhout JW,et al.Simultaneous humoral and cellular immune response against cancer- testis antigen NY- ESO- 1:definition of human histocompatibility leukocyte antigen (HLA)-A2binding peptide epitopes. The Journal of Experimental Medicine . 1998

[8] Chen YT,Scanlan MJ,Sahin U,et al.A testicular antigen aberrantly expressed in human cancers detected by autogous antibody screening. Proceedings of the National Academy of Sciences of the United States of America . 1997

[9] Gnjatic S,Jager E,Chen W,et al.CD8(+) T cell responses against a dominant cryptic HLA-A2 epitope after NY-ESO-1 peptide immunization of cancer patients. Proceedings of the National Academy of Sciences of the United States of America . 2002

[10] Dutoit V,Taub RN,Papadopoulos KP,et al.Multiepitope CD8+ T cell response to an NY-ESO-1 peptide vaccine results in imprecise tumor targeting. The Journal of Clinical Investigation . 2002

[1] Schultz-Thater E,Noppen C,Gudat F,et al.NY-SEO-1 tumour associated antigen is a cytoplasmic protein detectable by specific monoclonal antibodies in cell lines and clinical specimens. British Journal of Cancer . 2000

[2] Gnjatic S,Atanackovic D,Matsuo M,et al.Cross-presentation of HLA class I epitopes from exogenous NY-ESO-1 polypeptides by nonprofessional APCs. J Immunol . 2003

[3] Romero P,Dutoit V,Rubio-Godoy V,et al.CD8+ T-cell response to NY- ESO- 1: relative antigenicity and in vitro immunogenicity of natural and analogue sequences. Clinical Cancer Research .

[4] Gnjatic S,Nagata Y,Jager E,et al.Strategy for monitoring T cell responses to NY-ESO-1 in patients with any HLA class I allele. Proceedings of the National Academy of Sciences of the United States of America . 2000

[5] Jager E,Nagata Y,Gnjatic S,et al.Monitoring CD8+ T cell responses to NY-ESO-1: correlation of humoral and cellular immune responses. Proceedings of the National Academy of Sciences of the United States of America . 2000

[6] Zarour HM,Maillere B,Brusic V,et al.NY-ESO-1 119-143 is a promiscuous major histocompatibility complex class II T- helper epitope recognized by Th1- and Th2-type tumor-reactive CD4+T cells. Cancer Research . 2002

[7] Jager E,Chen YT,Drijfhout JW,et al.Simultaneous humoral and cellular immune response against cancer- testis antigen NY- ESO- 1:definition of human histocompatibility leukocyte antigen (HLA)-A2binding peptide epitopes. The Journal of Experimental Medicine . 1998

[8] Chen YT,Scanlan MJ,Sahin U,et al.A testicular antigen aberrantly expressed in human cancers detected by autogous antibody screening. Proceedings of the National Academy of Sciences of the United States of America . 1997

[9] Gnjatic S,Jager E,Chen W,et al.CD8(+) T cell responses against a dominant cryptic HLA-A2 epitope after NY-ESO-1 peptide immunization of cancer patients. Proceedings of the National Academy of Sciences of the United States of America . 2002

[10] Dutoit V,Taub RN,Papadopoulos KP,et al.Multiepitope CD8+ T cell response to an NY-ESO-1 peptide vaccine results in imprecise tumor targeting. The Journal of Clinical Investigation . 2002